SOURCE: Active Biotech

March 15, 2007 06:58 ET

The Election Committee's proposal for approval by the Annual General Meeting of Active Biotech

LUND, SWEDEN -- (MARKET WIRE) -- March 15, 2007 -- The Election Committee has notified Active Biotech that it will submit the following proposals, among others, for approval by the Annual General Meeting on April 19, 2007:

- The Election Committee proposes that the Board of Directors shall comprise six Members with no deputies.

- Sven Andréasson, Mats Arnhög, Peter Sjöstrand, Klas Kärre and Peter Ström shall be re-elected as Board Members.

- Magnhild Sandberg shall be elected as a new Member of the Board.

Magnhild Sandberg-Wollheim, MD PhD, is a Professor of Neurology and Chief Medical Officer at the neurological clinic at Lund University Hospital. Dr. Sandberg has forty years experience treating patients with multiple sclerosis and her research has largely focused on clinical, immunological and genetic problems of this disease. Dr Sandberg is a member of the Swedish Neurological Society , the American Academy of Neurology, the Royal Physiographic Society and is an honorary member of the Swedish MS Association.

The Election Committee's complete proposals for decisions at the Annual General Meeting and additional information concerning the Board Member up for election, as well as an account of the work of the Election Committee, will be presented in conjunction with the publication of the notification of the Annual General Meeting.

Lund, March 15, 2007
Active Biotech AB (publ)

Sven Andréasson
President and CEO

For further information, please contact:
Sven Andréasson
President and CEO
telephone: +46 (0)46-19 20 49

Cecilia Hofvander
Manager Corporate  Communication
telephone:  +46 (0)46-19 11 22
Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, the primary indication being renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer 57-57 for SLE and RhuDex® for RA. In addition, the preclinical development of the I-3D project is being conducted in cooperation with Chelsea Therapeutics.
Active Biotech AB ( 556223-9227)
P.O. Box 724, SE-220 07 Lund, Sweden
Tel +46 46-19 20 00
Fax +46 46-19 20 50

Copyright © Hugin ASA 2007. All rights reserved.

Contact Information